All In Biotech

Drug Trial Radar · NCT01369355

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease

Last checked: Nov 20, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,282 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,282

Actual

Start

Sep 13, 2011

Primary completion

Jun 10, 2015

Study completion Oct 1, 2019

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 8, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy and safety of 2 maintenance regimens of ustekinumab administered subcutaneously to patients with moderately to severely active Crohn's disease who responded to treatment with intravenous ustekinumab in studies CNTO1275CRD3001 and CNTO1275CRD3002, compared to subcutaneously administered placebo.

Conditions

  • Crohn's Disease
  • Colitis
  • IBD
  • Inflammatory Bowel Disease

Interventions

  • Placebo SCDrug

    Placebo will be administered subcutaneously.

  • Placebo IVDrug

    Placebo will be administered as a single Intravenous infusion at week 0.

  • Ustekinumab 90 mg SC q8wDrug

    Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.

  • Ustekinumab 130 mg IVDrug

    Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.

  • Ustekinumab 90 mg SC q12wDrug

    Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinical Remission at Week 44Time frame: Week 44

Locations

220 sites in 26 countries. Site status is shown where the registry gives one.

  • Site not named

    Tucson, Arizona

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Carlos, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Monica, California

  • Site not named

    Lone Tree, Colorado

  • Site not named

    New Haven, Connecticut

  • Site not named

    Boca Raton, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Naples, Florida

  • Site not named

    Weston, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Macon, Georgia

  • Site not named

    Idaho Falls, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Evanston, Illinois

  • Site not named

    Clive, Iowa

  • Site not named

    Pratt, Kansas

  • Site not named

    Crestview Hills, Kentucky

  • Site not named

    Lexington, Kentucky

  • Site not named

    Louisville, Kentucky

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Chevy Chase, Maryland

  • Site not named

    Towson, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Chesterfield, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Troy, Michigan

  • Site not named

    Ypsilanti, Michigan

  • Site not named

    Rochester, Minnesota

  • Site not named

    Jackson, Mississippi

  • Site not named

    Ocean Springs, Mississippi

Showing 40 of 220 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.